1. The use of glycoproteins isolated from the bacterium Klebsiella Pneumoniae, to obtain a medicinal product intended for the treatment of acute and chronic infectious diseases, in particular, in the case of the continuation of such diseases after treatment with antibiotics, and these glycoproteins are retained on a membrane with an average pore size of 0.011 μm and used in a dosage of 1 mg per tablet or sachet, or the use of membrane proteoglycans isolated from the bacterium Klebsiella pneumoniae in a dosage of 1.125 mg per tablet or capsule lu at an average dosage of 2 tablets per sut.2. The use of glycoproteins isolated from the bacterium Klebsiella Pneumoniae according to claim 1, characterized in that the drug is intended to treat general infections of the body. The use of glycoproteins isolated from the bacterium Klebsiella Pneumoniae according to claim 1, characterized in that the glycoproteins are used separately in the composition of the drug or in combination with antigenic lysates of various bacteria in various proportions, or with ribosomes of various bacteria, the percentage of RNA in which is 70%, in various compositions and proportions. 4. The use of glycoproteins isolated from the bacterium Klebsiella Pneumoniae according to claim 1 for the manufacture of a medicament, characterized in that said glycoproteins have the same chemical formula or different chemical formulas. The use of glycoproteins according to any one of claims 1 to 4, characterized in that said glycoproteins, due to very strong stimulation of the entire immune system, cause a significant increase in the total number of immunocompetent cells, a significant increase in the number of cells serving1. Применение гликопротеинов, выделенных из бактерии Klebsiella Pneumoniae, для получения лекарственного средства, предназначенного для лечения острых и хронических инфекционных заболеваний, в частности, в случае продолжения таких заболеваний после лечения антибиотиками, причем указанные гликопр
